[go: up one dir, main page]

MA35850B1 - Nouvelle utilisation thérapeutique d'antagonistes du récepteur p75 - Google Patents

Nouvelle utilisation thérapeutique d'antagonistes du récepteur p75

Info

Publication number
MA35850B1
MA35850B1 MA37184A MA37184A MA35850B1 MA 35850 B1 MA35850 B1 MA 35850B1 MA 37184 A MA37184 A MA 37184A MA 37184 A MA37184 A MA 37184A MA 35850 B1 MA35850 B1 MA 35850B1
Authority
MA
Morocco
Prior art keywords
receptor antagonists
therapeutic use
new therapeutic
medicament
prevention
Prior art date
Application number
MA37184A
Other languages
English (en)
Inventor
Roberta Avallone
Marco Baroni
Tiziano Croci
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47429839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35850(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA35850B1 publication Critical patent/MA35850B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne l'utilisation d'un antagoniste du récepteur p75 ou de ses sels pharmaceutiquement acceptables pour la préparation d'un médicament destiné à être utilisé dans le traitement et/ou la prévention de la vessie hyperactive.
MA37184A 2011-12-20 2014-07-07 Nouvelle utilisation thérapeutique d'antagonistes du récepteur p75 MA35850B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306709.4A EP2606894A1 (fr) 2011-12-20 2011-12-20 Nouvelle utilisation thérapeutique des antagonistes du récepteur p75
PCT/EP2012/076494 WO2013092918A1 (fr) 2011-12-20 2012-12-20 Nouvelle utilisation thérapeutique d'antagonistes du récepteur p75

Publications (1)

Publication Number Publication Date
MA35850B1 true MA35850B1 (fr) 2014-12-01

Family

ID=47429839

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37184A MA35850B1 (fr) 2011-12-20 2014-07-07 Nouvelle utilisation thérapeutique d'antagonistes du récepteur p75

Country Status (24)

Country Link
US (2) US20140296513A1 (fr)
EP (2) EP2606894A1 (fr)
JP (2) JP6275649B2 (fr)
KR (1) KR20140103151A (fr)
CN (1) CN104144688B (fr)
AR (1) AR089344A1 (fr)
AU (2) AU2012356922B2 (fr)
BR (1) BR112014014933A2 (fr)
CA (1) CA2859582A1 (fr)
CL (1) CL2014001619A1 (fr)
CO (1) CO6990740A2 (fr)
CR (1) CR20140298A (fr)
DO (1) DOP2014000137A (fr)
EA (1) EA028616B1 (fr)
HK (1) HK1198580A1 (fr)
IL (1) IL233189A0 (fr)
MA (1) MA35850B1 (fr)
MX (1) MX2014007673A (fr)
PE (1) PE20141854A1 (fr)
PH (1) PH12014501390A1 (fr)
SG (1) SG11201403390QA (fr)
TN (1) TN2014000269A1 (fr)
UY (1) UY34535A (fr)
WO (1) WO2013092918A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2606894A1 (fr) * 2011-12-20 2013-06-26 Sanofi Nouvelle utilisation thérapeutique des antagonistes du récepteur p75
CN117695286A (zh) 2017-06-06 2024-03-15 住友制药(苏州)有限公司 使用维贝隆以治疗膀胱过度活动症
JP7530182B2 (ja) * 2020-02-06 2024-08-07 株式会社東芝 生体適合部材

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3236243A1 (de) 1982-09-30 1984-04-05 Merck Patent Gmbh, 6100 Darmstadt Schwefelhaltige indolderivate
FR2744448B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
JP2001503397A (ja) 1996-10-21 2001-03-13 アレリックス バイオファーマシューティカルズ インコーポレイテッド ニューロトロフィンアンタゴニスト組成物
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2003514508A (ja) 1997-07-01 2003-04-15 ノボ ノルディスク アクティーゼルスカブ グルカゴン拮抗剤／逆作用剤
DE19826841A1 (de) 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazine
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
CA2369945A1 (fr) 1999-04-06 2000-10-12 James L. Kelley Thiopyrimidines neurotrophiques substitues
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
FR2803593B1 (fr) 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
UA77526C2 (en) 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
FR2862967B1 (fr) 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
FR2862968B1 (fr) 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
BRPI0514094A (pt) 2004-08-02 2008-05-27 Osi Pharm Inc composto, composição, e, método de tratamento de distúrbio hiperproliferativo
CN101304973A (zh) * 2005-09-15 2008-11-12 佩因赛普托药物公司 调节神经营养蛋白介导的活性的方法
AU2009221860A1 (en) 2008-03-05 2009-09-11 Targacept, Inc. Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes
EP2280968A2 (fr) 2008-03-24 2011-02-09 Medivation Technologies, Inc. Pyrido [3,4-b]indoles et leurs procédés d'utilisation
CN101284838B (zh) 2008-06-06 2011-05-04 天津药物研究院 含噻吩并吡啶的哌嗪类衍生物、其制备方法和用途
FR2932481B1 (fr) 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
FR2932482B1 (fr) 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
JP2010254641A (ja) * 2009-04-28 2010-11-11 Astellas Pharma Inc アゾールカルボキサミド化合物又はその塩
FR2953839A1 (fr) 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
FR2953836B1 (fr) 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
EP2606894A1 (fr) * 2011-12-20 2013-06-26 Sanofi Nouvelle utilisation thérapeutique des antagonistes du récepteur p75

Also Published As

Publication number Publication date
PE20141854A1 (es) 2014-12-11
BR112014014933A2 (pt) 2017-06-13
JP6275649B2 (ja) 2018-02-07
EP2793889A1 (fr) 2014-10-29
DOP2014000137A (es) 2014-07-31
US9763940B2 (en) 2017-09-19
AR089344A1 (es) 2014-08-13
SG11201403390QA (en) 2014-07-30
MX2014007673A (es) 2014-11-14
WO2013092918A1 (fr) 2013-06-27
CN104144688B (zh) 2017-03-22
TN2014000269A1 (en) 2015-09-30
EA201491226A1 (ru) 2014-10-30
US20170056400A1 (en) 2017-03-02
CL2014001619A1 (es) 2014-10-17
EP2606894A1 (fr) 2013-06-26
IL233189A0 (en) 2014-07-31
EA028616B1 (ru) 2017-12-29
JP2018030865A (ja) 2018-03-01
NZ626485A (en) 2016-11-25
PH12014501390A1 (en) 2014-09-22
CO6990740A2 (es) 2014-07-10
HK1198580A1 (en) 2015-04-30
JP2015500863A (ja) 2015-01-08
AU2012356922A1 (en) 2014-07-17
CR20140298A (es) 2014-10-29
UY34535A (es) 2013-07-31
AU2017248550A1 (en) 2017-11-09
CN104144688A (zh) 2014-11-12
AU2012356922B2 (en) 2017-11-09
CA2859582A1 (fr) 2013-06-27
US20140296513A1 (en) 2014-10-02
KR20140103151A (ko) 2014-08-25

Similar Documents

Publication Publication Date Title
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
EP2750660A4 (fr) Administration à libération prolongée d'agents actifs pour traiter le glaucome et l'hypertension oculaire
MA37888A1 (fr) Composition pharmaceutique enrobée contenant du régorafenib
MA37850A1 (fr) Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
MA35156B1 (fr) 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoléin-2-one destinée à être utilisée dans le traitement du carcinome adénoïde kystique
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201790406A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MA35850B1 (fr) Nouvelle utilisation thérapeutique d'antagonistes du récepteur p75
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA45639B1 (fr) Combinaison d'antagonistes purs du récepteur 5-ht6 avec des inhibiteurs d'acétylcholinestérase
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
IN2015DN04172A (fr)
TN2012000563A1 (fr) Nouvelle association entre le 4(3-(cis-hexahydrocyclopenta(c)pyrrol-2(1-h)-yl)propoxy)benzamide et un antagoniste des recepteurs nmda et les compositions pharmaceutiques qui la contiennent.
MA45002B1 (fr) Triple combinaison d'antagonistes purs du récepteurs 5-ht6, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteur nmda
MA39032A1 (fr) Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë
BR112014027496A2 (pt) biodisponibilidade de metilnaltrexona oral aumenta com uma formulação à base de fosfatidilcolina
MA39833A (fr) Nouvelle utilisation du n,n-bis-2-mercaptoéthyl isophtalamide
FI3903774T3 (fi) N,N-bis-2-merkaptoetyyli-isoftalamidi neurodegeneratiivisten sairauksien hoitoon
FR2985907A1 (fr) Composition pharmaceutique pour le traitement des dysfonctions erectiles
RU2011134582A (ru) Ингибирующее дипептидилпептидазу iv средство и фармацевтическая композиция на его основе
MX2014014813A (es) Uso de agonistas o antagonistas inversos para el receptor de grelina para tratar trastornos del sueño.
MX385719B (es) Combinacion de un antagonista del receptor 5-ht6 y un inhibidor de acetilcolinesterasa para su uso en el tratamiento de la enfermedad de alzheimer en una subpoblacion de pacientes portadores de alelos apoe4
MA57504B1 (fr) Forme cristalline d'hydrogénosulfate de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide